Market Access Jazz and Lilly cancer drugs cleared for use by NHS PharmaphorumJazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.Market AccessOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance. Market AccessOncologyRead full story Post navigation Previous: The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain GroundNext: Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls Related Stories Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug pharminent May 11, 2026 Market Access Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point pharminent May 5, 2026 Market Access Where Gross-to-net Pressure Actually Lives After Launch pharminent May 1, 2026
